References
- Soucie JM, Evatt B, Jackson D; Hemophilia Surveillance Systems Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol 1998;59(4):288–94. doi: 10.1002/(sici)1096-8652(199812)59:4<;288::aidajh4>3.0.co;2-i.
- Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males. A meta-analytic approach using national registries. Ann Intern Med 2019; 171(8): 540–546. doi: 10.7326/M19-1208.
- Morais SA, du Preez HE, Akhtar MR, Cross S, Isenberg DA. Musculoskeletal complications of haematological disease. Rheumatology (Oxford) 2016; 55(6): 968–81. doi: 10.1093/rheumatology/kev360.
- Dutta A, Dutta TS, Dey P. Clinical profile of haemophilia patients of upper Assam—a hospital-based study. J Evol Med Dent Sci 2017;6(37): 2990–4.
- Gavrel M, Rafowicz A, D’Oiron R, Franchi-Abella S, Lambert T, Adamsbaum C. Imaging features of atypical bleeds in young patients with hemophilia. Diagn Interv Imaging 2019; 100(3): 135–45. doi: 10.1016/j.diii.2018.11.010.
- Eshghi P, Khafafpour Z, Malek F, Habibpanah B. Massive spontaneous hemothorax in a child with hemophilia. Iran J Blood Cancer 2019; 11(4): 148–9.
- Carcao M, Goudemand J. Inhibitors in Hemophilia: A Primer. Fifth edition. 2018. Montréal: World Federation of Hemophilia. Available at
https://www1.wfh.org/publication/files/pdf-1122.pdf (accessed 13 April 2022). - Oldenburg J, Mahlangu J, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–818. doi: 10.1056/NEJMoa1703068.
- Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol 2018; 11(11): 835–846. doi: 10.1080/17474086.2018.1531701.
- Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9(4): 418–35. doi: 10.1046/j.1365-2516.2003.00780.x.
- Pinto P, Shelar T, Nawadkar V, et al. The epidemiology of FVIII inhibitors in Indian haemophilia A patients. Indian J Hematol Blood Transfus 2014; 30(4):356–63. doi: 10.1007/s12288-014-0342-z.
- Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41(1 Suppl 1); 82–8. doi: 10.1053/j.seminhematol.2003.11.016.
- Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113(3): 600–3. doi: 10.1046/j.1365-2141.2001.02828.x.
- Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4(1): 59–72. doi: 10.1177/2040620712464509.
- Sachdeva A, Gunasekaran V, Ramya HN, et al. Consensus statement of the Indian Academy of Pediatrics in diagnosis and management of hemophilia. Indian Pediatr 2018; 55(7): 582–90.
- Radhakrishnan N, Shankar R, Maji M, Rana M. Initial experience of Emicizumab prophylaxis in children with inhibitor positive severe hemophilia A from a single center in India. Pediatr Hematol Oncol J 2021; 6(2): 97–99. doi: 10.1016/j.phoj.2021.03.0004.
- Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol 2019; 102(2): 111–22. doi: 10.1111/ejh.13193.